UnitedHealth (UNH) stock collapsed 20% on January 27, 2026, after the company reported Q4 earnings that missed revenue estimates and issued a disappointing 2026 outlook projecting revenue over $439 billion (versus $454.6 billion expected), a 2% year-over-year decline. The selloff intensified following reports that the Trump administration proposed essentially flat Medicare Advantage payment rates for 2027 (just 0.09% increase), significantly below industry expectations and threatening margins across the sector.
Key Drivers of the UNH Stock Move
- Primary Catalyst: The combination of a revenue miss, weak 2026 guidance signaling a planned “right-sizing across the enterprise,” and Medicare rate pressure from federal regulators created a perfect storm for the healthcare giant.
- Bull Case: Management emphasized the business is “meaningfully stronger” than six months ago and expects Medicare margins to improve by approximately 50 basis points from 2025 levels. The company projects 6% to 7% rate increases in 2026 and remains encouraged by January performance, finding markets “firm and competitive.”
- Bear Case: Elevated medical costs continue to pressure profitability, with management expecting medical care activity to remain at current elevated trend levels through 2026. The essentially flat Medicare rates for 2027 represent a structural headwind that contradicts management’s claims about medical utilization and cost trends.
The setup remains precarious despite management’s optimism. UnitedHealth’s shift toward margin-focused strategy in 2026 reflects acknowledgment that revenue growth faces significant headwinds. The Medicare rate decision, combined with persistently elevated medical costs that plagued 2025 results (Q3 EPS down 59% year-over-year, Q4 down 69%), suggests the company faces sustained margin compression that could persist well into 2027.
UNH Smart Money Activity
Insider activity shows routine stock awards to executives and directors throughout December 2025 and early January 2026, with no significant open-market purchases or sales.
However, congressional trading reveals notable timing: Representative Kevin Hern (R) sold $250,000 to $500,000 worth of UNH stock on December 23, 2025, just weeks before the Medicare rate announcement and earnings collapse. Other members showed mixed activity, with small purchases in November and December by representatives from both parties, followed by sales by Democrats Gilbert Cisneros and Julie Johnson in November and December.
UNH Unusual Options
Options activity on January 27 exploded with over 200 unusual transactions totaling millions in premium. The flow was decidedly mixed but leaned protective, with large put sweeps dominating: a $646,300 sweep on Jan 2027 $600 calls (likely closing long positions), $390,300 in Feb 2026 $300 puts, and $360,800 in Apr 2026 $280 puts. Near-term activity centered on Jan 30, 2026 expiration, with massive volume on $285 calls and puts as traders positioned for continued volatility. The Dec 2026 $400 call sweep for $311,900 (bearish at bid) and multiple long-dated put purchases suggest investors anticipate extended weakness.
UNH Analyst Focus
Analyst activity remains sparse but cautious. Morgan Stanley maintained its Overweight rating on January 23 but lowered the price target from $411 to $409, while Barclays confirmed Buy with a modest increase from $386 to $391 on January 5. The lack of fresh analyst commentary following the earnings disaster is notable. Prior coverage emphasized elevated medical costs as the key concern heading into Q4 results, a worry that proved well-founded.
UNH Seasonality
Based on 12+ years of historical data, UNH shows pronounced seasonal weakness in January and February, with January posting positive returns only 38% of the time (average change of negative 1.4%) and February succeeding just 42% of the time (average negative 1.9%). The stock typically strengthens from May through August and shows particularly strong performance in October (67% positive, average 5.1% gain) and November (67% positive, 4.3% average). This seasonal headwind adds to near-term bearish pressure.
UNH Relative Performance
The stock’s relative performance versus healthcare sector peers has collapsed dramatically. UNH ranked at the 78th percentile within its sector in late October 2025, meaning it outperformed 78% of healthcare stocks. By mid-December, this plummeted to the 40th percentile, and following the January 27 collapse, the stock sits near the 53rd percentile. This represents a stunning reversal from sector leadership to middle-of-the-pack mediocrity in just three months, reflecting sustained underperformance even before today’s 20% drop.
Market Update Into September 7th: Inflation Data Incoming